İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2018 · article

Effects of perineural invasion in prostate needle biopsy on tumor grade and biochemical recurrence rates after radical prostatectomy

YÖKSİS OpenAlex Açık erişim · gold
Yıl2018
Atıf10OpenAlex
Atıf10Semantic Scholar · 1 etkili
Yüzdelik%77,6
FWCI1,131,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q4

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıThe Kaohsiung Journal of Medical Sciences
  • Katalog eşleşmesi (ISSN)Kaohsiung Journal of Medical Sciences
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

To predict local invasive disease before retropubic radical prostatectomy (RRP), the correlation of perineural invasion (PNI) on prostate needle biopsy (PNB) and RRP pathology data and the effect of PNI on biochemical recurrence (BR) were researched. For patients with RRP performed between 2005 and 2014, predictive and pathologic prognostic factors were assessed. Initially all and D'Amico intermediate-risk group patients were comparatively assessed in terms of being T2 or T3 stage on RRP pathology, positive or negative for PNI presence on PNB and positive or negative BR situation. Additionally the effect of PNI presence on recurrence-free survival (RFS) rate was investigated. When all patients are investigated, multivariate analysis observed that in T3 patients PSA, PNB Gleason score (GS) and tumor percentage were significantly higher; in PNI positive patients PNB GS, core number and tumor percentage were significantly higher and in BR positive patients PNB PNI positivity and core number were significantly higher compared to T2, PNI negative and BR negative patients, separately (p < 0.05). When D'Amico intermediate-risk patients are evaluated, for T3 patients PSA and PNB tumor percentage; for PNI positive patients PNB core number and tumor percentage; and for BR positive patients PNB PNI positivity were significantly higher compared to T2, PNI negative and BR negative patients, separately (p < 0.05). Mean RFS in the whole patient group was 56.4 ± 4.2 months for PNI positive and 96.1 ± 5.7 months for negative groups. In the intermediate-risk group, mean RFS was 53.7 ± 5.1 months for PNI positive and 100.3 ± 7.7 months for negative groups (p < 0.001). PNI positivity on PNB was shown to be an important predictive factor for increased T3 disease and BR rates and reduced RFS.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

10atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 11 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2021 Are the Recommended Criteria for Clinically Insignificant Prostate Cancer Applicable to 12-core Prostate Biopsy Scheme? A Multicentre Study of Urooncology Association, TurkeyAtıf 2 · OpenAlex
  2. 2021 Are the Recommended Criteria for Clinically Insignificant Prostate Cancer Applicable to 12-core Prostate Biopsy Scheme? A Multicentre Study of Urooncology Association, TurkeyAtıf 2 · OpenAlex
  3. 2021 Are the Recommended Criteria for Clinically Insignificant Prostate Cancer Applicable to 12-core Prostate Biopsy Scheme? A Multicentre Study of Urooncology Association, TurkeyAtıf 2 · OpenAlex
  4. 2021 Are the Recommended Criteria for Clinically Insignificant Prostate Cancer Applicable to 12-core Prostate Biopsy Scheme? A Multicentre Study of Urooncology Association, TurkeyAtıf 2 · OpenAlex
  5. 2024 The Effect of Perineural Invasion on Biochemical Recurrence-free Survival Following Nerve-sparing Radical ProstatectomyAtıf 1 · OpenAlex
  6. 2024 The Effect of Perineural Invasion on Biochemical Recurrence-free Survival Following Nerve-sparing Radical ProstatectomyAtıf 1 · OpenAlex
  7. 2022 Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, TurkeyAtıf 1 · OpenAlex
  8. 2022 Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, TurkeyAtıf 1 · OpenAlex
  9. 2022 Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, TurkeyAtıf 1 · OpenAlex
  10. 2021 Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, TurkeyAtıf 1 · OpenAlex

Yazarlar

7
  1. SERDAR ÇELİK 1
  2. OZAN BOZKURT 2
  3. ÖMER DEMİR 3
  4. Özgür Gürboğa 4
  5. EMİNE BURÇİN TUNA 5
  6. KUTSAL YÖRÜKOĞLU DOKUZ EYLÜL ÜNİVERSİTESİ 6
  7. GÜVEN ASLAN 7